After trailing its peers, the drug maker has finally caught up after getting past a blockbuster drug patent expiry
The Globe and Mail
Mon, 12/10/2012 - 2:15pm
After trailing its peers, the drug maker has finally caught up after getting past a blockbuster drug patent expiry